About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

WITHDRAWNPhase 2

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

NCT01238783•Alcon Research

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Bacterial Conjunctivitis

Interventions

AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension

AL-15469A 0.5%

+2 more

Key Dates

Start Date

January 1, 2011

Primary Completion Date

December 1, 2011

Last Updated

December 1, 2011

Related Studies

COMPLETEDPhase 3

Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis

NCT02432807

Bacterial Conjunctivitis

COMPLETEDPhase 3

A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

NCT00347932

Acute Bacterial Conjunctivitis

TERMINATEDPhase 3

Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

NCT01330355

Bacterial Conjunctivitis

Sponsors

Lead Sponsor

Alcon Research

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 1, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions